about
Drug delivery nanoparticles in skin cancersDecreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia.Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells.Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells In Vitro and Mouse Experimental Autoimmune Encephalomyelitis In Vivo.Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models.Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis.Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.Solid lipid nanoparticles carrying lipophilic derivatives of doxorubicin: preparation, characterization, and in vitro cytotoxicity studies.In Vitro and In Vivo Therapeutic Evaluation of Camptothecin-Encapsulated β-Cyclodextrin Nanosponges in Prostate Cancer.GSH-targeted nanosponges increase doxorubicin-induced toxicity "in vitro" and "in vivo" in cancer cells with high antioxidant defenses.A mutation in caspase-9 decreases the expression of BAFFR and ICOS in patients with immunodeficiency and lymphoproliferation.Triggering of B7h by the ICOS modulates maturation and migration of monocyte-derived dendritic cells.IL-17 protects T cells from apoptosis and contributes to development of ALPS-like phenotypes.Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary in vitro studies.Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.ICOS-Ligand Triggering Impairs Osteoclast Differentiation and Function In Vitro and In Vivo.Development and Characterization of Solid Lipid Nanoparticles Loaded with a Highly Active Doxorubicin Derivative.Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors.B7h triggering inhibits the migration of tumor cell lines.Glutathione/pH-responsive nanosponges enhance strigolactone delivery to prostate cancer cellsDevelopment of Solid Lipid Nanoparticles by Cold Dilution of Microemulsions: Curcumin Loading, Preliminary In Vitro Studies, and BiodistributionAdaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASHSubcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitisCyclic nigerosyl-1,6-nigerose-based nanosponges: An innovative pH and time-controlled nanocarrier for improving cancer treatmentPaclitaxel-Loaded Nanosponges Inhibit Growth and Angiogenesis in Melanoma Cell ModelsImprovement in the Anti-Tumor Efficacy of Doxorubicin Nanosponges in In Vitro and in Mice Bearing Breast Tumor ModelsImmunotherapy of experimental melanoma with ICOS-Fc loaded in biocompatible and biodegradable nanoparticlesAnti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activityNanoemulsions as Delivery Systems for Poly-Chemotherapy Aiming at Melanoma Treatment
P50
Q28390405-799E09BD-7D7E-465C-AAA6-03D14DF18999Q33433741-4D5629FB-0DAE-43FD-BEC9-164F8DEC3115Q36159180-B24526E9-18B7-4588-941D-9D3A23FCEA46Q37127970-7CF0BD05-7346-4881-B8E0-DE5C4F949A39Q37327348-77D12D8D-C534-4E76-95B5-5099726CD1B6Q37690125-49144184-D2D4-4521-AEC1-FDB1FBD52AA1Q37716786-CD168D65-0ECC-4F41-814C-8752B560C0FDQ38760799-96DD5098-611A-4C34-A4E5-E33F173101F5Q38764500-2534B1B1-B639-43F6-8B06-6845683F1FCDQ38866629-7459988B-0662-40D4-B278-C27A2B429AA2Q41609169-5216EAF4-2940-4232-9B5C-677CF6819E47Q44752446-A8A4BEC0-02AE-4697-8601-3EFD549D2A64Q45115236-1D738939-44DE-413A-B0A0-E79ACB323F12Q48144711-2D99131A-6FA9-4D4C-9C52-83D60C03203CQ48175785-E48A4C5E-22D9-4F31-A341-67B5DD21E351Q48261321-DB410611-8972-42F3-AFEB-E54F8F0F3472Q49805176-1CB946F7-3EC1-43F7-ABBD-D3619B1F8407Q52778675-BA1FE7E7-0CD6-46F1-B202-758E89FE8806Q54360215-67C72194-9A7D-4A52-B40F-37F22CF772A9Q59794428-D9C89848-165A-42D6-9842-4C1337C7ECD7Q64251694-65CFE0A6-5598-481C-B6FA-5AC2DAFDED26Q86506810-074F606A-0D17-45B4-8DCD-938C90287EB0Q87642588-5CE181FD-F26C-48C6-BF0D-AD219CF8CCD1Q88865677-9749DF02-7A61-4606-95E7-AFEB51A13C6AQ92237995-1AA495D6-4165-41B0-B1AE-B500FE164C95Q92635367-582DC205-0B8F-4936-8441-213811DCC59CQ92803919-2591FEA2-7FC1-40C0-AE3E-51EB6374F9CDQ92965400-04D4470D-913C-49A9-A08B-A3102D7BAF72Q94592070-677D684E-45C1-451B-BC2F-A3C8D5A81972
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Casimiro Luca Gigliotti
@ast
Casimiro Luca Gigliotti
@en
Casimiro Luca Gigliotti
@es
Casimiro Luca Gigliotti
@nl
type
label
Casimiro Luca Gigliotti
@ast
Casimiro Luca Gigliotti
@en
Casimiro Luca Gigliotti
@es
Casimiro Luca Gigliotti
@nl
prefLabel
Casimiro Luca Gigliotti
@ast
Casimiro Luca Gigliotti
@en
Casimiro Luca Gigliotti
@es
Casimiro Luca Gigliotti
@nl
P106
P1153
36614333800
P21
P31
P496
0000-0002-3127-5686